title: Immune thrombocytopenic purpura and pregnancy.
abstract: Neonatal thrombocytopenia is a potentially life-threatening complication of immune thrombocytopenic purpura (ITP). We followed 23 pregnant women who had either a history of ITP (11 women) or clinically active disease (12 women) to delineate the factors responsible for neonatal thrombocytopenia. No relation was observed between maternal and neonatal platelet counts (P greater than 0.5). Eleven women delivered thrombocytopenic children; antiplatelet antibodies were detectable in each mother, including five who were in clinical remission at delivery. The level of platelet-associated IgG in the mothers did not identify the neonates at risk for thrombocytopenia (P greater than 0.05). However, the level of maternal circulating antiplatelet antibody correlated with both the presence and the extent of neonatal thrombocytopenia (P less than 0.005). A discrepancy between maternal platelet count and maternal antibody level may be especially notable in mothers treated with steroids or splenectomy. Monitoring the level of circulating antiplatelet antibody may help in identifying and managing pregnant women with ITP at risk of delivering neonates with serious thrombocytopenia.
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000906:Antibodies / Q000032:analysis; D001792:Blood Platelets / Q000276:immunology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000097:blood / Q000209:etiology*; D010976:Platelet Count; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000276:immunology*; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy / Q000276:immunology*; D013921:Thrombocytopenia / Q000097:blood / Q000209:etiology*
chemical_list: D000305:Adrenal Cortex Hormones; D000906:Antibodies; D007074:Immunoglobulin G